Skip Navigation

Cardiovascular Research 2003 59(4):980-987; doi:10.1016/S0008-6363(03)00520-0
© 2003 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Wagenaar, L. J
Right arrow Articles by van Gilst, W. H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wagenaar, L. J
Right arrow Articles by van Gilst, W. H
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2003, European Society of Cardiology

Differential localisation of the renin–angiotensin system in de-novo lesions and in-stent restenotic lesions in in-vivo human coronary arteries

Lodewijk J Wagenaara, Ad J van Bovena, Allard C van der Walb, Giovanni Amorosoa, René A Tioa, Chris M van der Loosb, Anton E Beckerb and Wiek H van Gilsta,*

aDepartment of Cardiology, Thoraxcenter, University Hospital of Groningen, Groningen, The Netherlands
bDepartment of Cardiovascular Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

w.h.van.gilst{at}med.rug.nl

* Corresponding author. Department of Clinical Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands. Tel.: +31-50-363-2811; fax: +31-50-363-2812.

Objective: Different components of the renin–angiotensin system (RAS) have been demonstrated in atherosclerotic plaques. However, the involvement of the RAS in in-stent restenosis is not clear. We studied the differential immunolocalisation of angiotensin converting enzyme (ACE) and the angiotensin II type 1 (AT1) receptor in de-novo stenotic lesions and in-stent restenotic lesions in human coronary arteries. Methods: Using a pullback atherectomy catheter, biopsies from de-novo coronary lesions (n=19) and in-stent restenotic lesions (n=19) were obtained. The biopsies were immunostained for vascular smooth muscle cells (VSMCs), macrophages, ACE and the AT1 receptor. Results: In biopsies from de-novo stenotic lesions ACE-positive macrophages were more numerous than in in-stent restenotic lesions (P=0.002). Moreover, in the latter lesions, ACE-positive macrophages decreased when the time interval of stent implantation was longer. On the other hand, in-stent restenotic lesions contained predominantly young VSMCs, which abundantly expressed AT1 receptors. Conclusions: Lesional ACE expression is not a prominent feature of in-stent restenotic lesions. In contrast, AT1 receptors are abundantly expressed on young VSMCs. In de-novo lesions ACE and AT1 receptors were found on macrophages and VSMCs, which were present in all specimens.

KEYWORDS Renin angiotensin system; Receptors; Coronary disease; Stents; Restenosis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.